Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
100 participants
INTERVENTIONAL
2025-04-22
2028-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bilateral Essential Tremor Treatment With FUS
NCT04501484
A Second Magnetic Resonance Guided Focused Ultrasound Thalamotomy for Essential Tremor
NCT04720469
Continued Access Protocol: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
NCT02289560
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) for Treatment of Tremor
NCT01932463
Analysis of Clinical Outcomes in Patients Undergoing Magnetic Resonance-Guided Focused Ultrasound for Medication-Refractory Tremor
NCT07212244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients assigned to the treatment arm will receive staged bilateral Exablate thalamotomy. Patients assigned to control group will remain under local standard medical treatment.
The primary efficacy study objective is to demonstrate that Exablate staged-bilateral thalamotomy treatment reduces tremor, as measured by Treated Upper Limb CRST (A+B) (0-28) score, to a higher extent than those remaining on previous unilateral Exablate thalamotomy at 6 months.
The primary safety study objective is to assess the adverse events (AEs) of Exablate staged-bilateral thalamotomy treatment in comparison to those remaining on unilateral treatment (control group) plus medical treatment, including AE type, incidence, severity and duration at 6 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
The video recordings are played in random order with respect to patients and study time points to minimize reviewer bias.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Exablate Arm
Subjects will receive staged bilateral Exablate thalamotomy.
Staged bilateral Exablate thalamotomy
Staged bilateral Exablate thalamotomy in ET patients
Control Arm
Subjects will continue with their standard of care treatment for 6 months.
Local standard medical treatment after previous Exablate unilateral thalamotomy.
Local standard medical treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Staged bilateral Exablate thalamotomy
Staged bilateral Exablate thalamotomy in ET patients
Local standard medical treatment after previous Exablate unilateral thalamotomy.
Local standard medical treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willing to participate in the study (i.e., signed ICF). (Willing to be randomized).
3. Patient is able to undergo a high-resolution Computerized Tomography (CT) scan.
4. Patient is able to fit into MRI unit and comply with all contraindications for the specific magnetic resonance (MR) system including and limited to contrast medium should there be needed.
5. The thalamus, sub-thalamus and the pallidum must be apparent on MR imaging.
6. Patient is able to communicate sensations to the physician during the procedure; Procedure does not require general anesthesia.
7. Patient must be able to use the Stop Sonication button freely.
8. Patient willing to have their head shaved prior to the actual treatment.
9. Patient has no history for claustrophobia which is not responding to medications.
10. ET patients who are eligible for second side staged bilateral Exablate thalamotomy treatment. Time since first intervention is at least 9 months.
11. Available tremor assessment prior to the unilateral Exablate thalamotomy.
12. Patients randomized to the study, irrespective of group allocation should be willing and able to remain in the study for at least 6 months and able to complete the required assessments.
Exclusion Criteria
2. Patients with MRI related contraindications (e.g. presence of metallic implants incompatibility with MRI, severe claustrophobia, reaction to contrast medium).
3. Patients in whom it is not possible to avoid energy absorbing structures or sensitive tissues (e.g., skull implants, surgical clips, shunts, electrodes, dura patch, skull patch, electrodes, etc.) from the path of the ultrasound beam.
4. Patients with concurrent active infections disease and/or severe allergies with fever.
5. Patients that have been diagnosed with brain tumors or a vascular anomaly.
6. Patients with a history of seizures, brain hemorrhages, stroke within the past year, or any coagulopathy.
7. Patients under anticoagulants and/or anti-platelets drugs known to increase bleeding risk within the duration defined by the half-life of the specific drugs.
8. Patient that has been given any contrast agent (e.g., CT, MRI), within 24 hours before treatment
9. Severe unstable hypertension that cannot be controlled by medications (diastolic Blood Pressure \> 100 on medication).
10. Patients with unstable cardiac status.
11. Patients exhibiting any behavior(s) consistent with ethanol or substance abuse.
12. Cerebrovascular disease (multiple CVA or CVA within 6 months).
13. Patients with risk factors for intraoperative or postoperative bleeding.
14. Imaging shows abnormal finding in CT or/and MRI (e.g., brain tumor, brain vascular malformation, shunt, etc.).
15. Patient has physical subscale score ≥ 16.5 on the Dysphagia Handicap Index or has been diagnosed with dysphagia.
16. Patient with cognitive impairment.
17. Patient with clinically significant abnormal speech function as determined by a speech pathologist.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
InSightec
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Günther Deuschl
Role: PRINCIPAL_INVESTIGATOR
Universitätsklinikum Schleswig-Holstein, Campus Kiel (UKSH)
Steffen Paschen
Role: PRINCIPAL_INVESTIGATOR
Universitätsklinikum Schleswig-Holstein, Campus Kiel (UKSH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turku University Hospital
Turku, , Finland
Universitätsklinikum Schleswig-Holstein, Campus Kiel (UKSH)
Kiel, , Germany
Fondazione IRCCS Istituto Neurologico Carlo Besta
Milan, , Italy
Germans Trias i Pujol Hospital
Badalona, , Spain
HM CINAC- Hospital Universitario HM Puerta del Sur
Móstoles, , Spain
Clinica Universidad de Navarra
Pamplona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ET006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.